Literature DB >> 8839832

A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages.

R Horie1, K Ito, M Tatewaki, M Nagai, S Aizawa, M Higashihara, T Ishida, J Inoue, H Takizawa, T Watanabe.   

Abstract

We identified and cloned cDNAs for two novel CD30 mRNAs of 2.3 kb that are induced by 12-O-tetradecanoylphorbol 13-acetate (TPA) in the human myeloid leukemia cell line HL-60. These transcripts were transcribed from the intronic region just upstream of the exon coding for the transmembrane domain of the CD30 protein. The shorter cDNA had a deletion of 54 nucleotides corresponding to the 3' region of the transmembrane domain of the CD30 and which was probably caused by alternative splicing. Translation of these transcripts appeared to start from the internal methionine codon at nucleotide position 289 that corresponds to that of 1612 in the CD30 cDNA, and encode a protein of 132 amino acid residues which corresponds exactly to the C-terminal cytoplasmic domain of CD30 protein. The calculated molecular mass of this variant CD30 (CD30v) protein was 14,087. Thus, the predicted CD30v protein retains most of the cytoplasmic region, but lacks the extracellular and transmembrane domains. Northern blots detected the expression of CD30v transcripts only in the lung and the TPA-stimulated HL-60 cell line. Translation of this mRNA in vitro produced a protein of 25 kD. Immunoblotting analysis with HCD30C1, a rabbit polyclonal antibody raised against the cytoplasmic domain of CD30 protein, detected proteins with an apparent Mr 25 kD expressed in TPA-stimulated HL-60 and COS-7 cells that were transfected with both types of CD30v cDNAs. Constitutive phosphorylation of the CD30v protein was demonstrated by in vitro labeling with [32P]. Immunohistochemical studies demonstrated CD30v protein was in alveolar macrophages. Cotransfection experiments using a kappa B-site-dependent reporter construct showed that CD30v can transactivate gene expression through activation of NF kappa B, as was noted on the authentic CD30 protein. Overexpression of the CD30v induced differentiation of HL-60 cells as evidenced by an increased NBT reduction activity. These observations provided new insights into the molecular heterogeneity and biological function of CD30 in myeloid cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8839832

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms.

Authors:  R Horie; V Gattei; K Ito; S Imajo-Ohmi; T Tange; J Miyauchi; A Pinto; M Degan; A De Iuliis; F Tassan Mazzocco; F M Rossi; M Higashihara; T Watanabe
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Expression of CD30 mRNA, CD30L mRNA and a variant form of CD30 mRNA in restimulated peripheral blood mononuclear cells (PBMC) of patients with helminthic infections resembling a Th2 disease.

Authors:  J Kilwinski; T Berger; J Mpalaskas; S Reuter; W Flick; P Kern
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.

Authors:  A Cerutti; A Schaffer; R G Goodwin; S Shah; H Zan; S Ely; P Casali
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

4.  Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

Authors:  Mariko Watanabe; Kinji Itoh; Tomiteru Togano; Marshall E Kadin; Toshiki Watanabe; Masaaki Higashihara; Ryouichi Horie
Journal:  Am J Pathol       Date:  2011-11-19       Impact factor: 4.307

5.  AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells.

Authors:  Mariko Watanabe; Yuji Ogawa; Kinji Ito; Masaaki Higashihara; Marshall E Kadin; Lawrence J Abraham; Toshiki Watanabe; Ryouichi Horie
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

6.  Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation.

Authors:  Masaya Higuchi; Takehiro Matsuda; Naoki Mori; Yasuaki Yamada; Ryouichi Horie; Toshiki Watanabe; Masahiko Takahashi; Masayasu Oie; Masahiro Fujii
Journal:  Retrovirology       Date:  2005-05-06       Impact factor: 4.602

7.  SUV39H1 interacts with HTLV-1 Tax and abrogates Tax transactivation of HTLV-1 LTR.

Authors:  Koju Kamoi; Keiyu Yamamoto; Aya Misawa; Ariko Miyake; Takaomi Ishida; Yuetsu Tanaka; Manabu Mochizuki; Toshiki Watanabe
Journal:  Retrovirology       Date:  2006-01-13       Impact factor: 4.602

8.  TRAF2 recruitment via T61 in CD30 drives NFκB activation and enhances hESC survival and proliferation.

Authors:  Nilay Y Thakar; Dmitry A Ovchinnikov; Marcus L Hastie; Bostjan Kobe; Jeffrey J Gorman; Ernst J Wolvetang
Journal:  Mol Biol Cell       Date:  2015-01-07       Impact factor: 4.138

9.  CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.

Authors:  Hinrich P Hansen; Ahmad Trad; Maria Dams; Paola Zigrino; Marcia Moss; Maximilian Tator; Gisela Schön; Patricia C Grenzi; Daniel Bachurski; Bruno Aquino; Horst Dürkop; Katrin S Reiners; Michael von Bergwelt-Baildon; Michael Hallek; Joachim Grötzinger; Andreas Engert; Adriana F Paes Leme; Elke Pogge von Strandmann
Journal:  Oncotarget       Date:  2016-05-24

10.  Study of the expression of CD30 in pterygia compared to healthy conjunctivas.

Authors:  Yonathan Garfias; Víctor Manuel Bautista-De Lucio; Cynthia García; Angel Nava; Leonardo Villalvazo; María Carmen Jiménez-Martínez
Journal:  Mol Vis       Date:  2009-10-17       Impact factor: 2.367

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.